SOLV
Solventum Corporation
NYSE · Healthcare · Medical - Care Facilities · US
$91.69
−0.81%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.3B | 8.3B | 8.3B | 8.2B | 8.1B |
| Cost of Revenue | 3.8B | 3.9B | 3.7B | 3.5B | 3.4B |
| Gross Profit | 4.5B | 4.5B | 4.6B | 4.7B | 4.7B |
| Operating Expenses | |||||
| R&D Expense | 726.0M | 739.0M | 775.0M | 758.0M | 767.0M |
| SG&A Expense | 3.3B | 3.1B | 2.8B | 2.2B | 2.2B |
| General & Admin Expense | 827.0M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.6B) | (1.5B) | — | — | — |
| Total Operating Expenses | 2.5B | 2.3B | 3.6B | 3.0B | 3.0B |
| Cost and Expenses | 6.2B | 6.1B | 7.2B | 6.5B | 6.4B |
| Operating Income (EBIT) | 2.1B | 2.2B | 1.0B | 1.7B | 1.7B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 266.0M | 347.0M | 367.0M | — | — |
| Net Interest Income | (266.0M) | (347.0M) | (367.0M) | — | — |
| Other Non-Op Income/Expense | (381.0M) | (468.0M) | (431.0M) | (25.0M) | (1.0M) |
| Non-Operating Income (excl Interest) | 115.0M | 121.0M | 64.0M | 25.0M | 1.0M |
| EBT (Pre-Tax Income) | 1.7B | 1.7B | 605.0M | 1.7B | 1.7B |
| Income Tax Expense | 261.0M | 157.0M | 127.0M | 321.0M | 349.0M |
| Bottom Line | |||||
| Net Income | 1.4B | 1.6B | 479.0M | 1.3B | 1.3B |
| Earnings from Cont. Ops | 1.4B | 1.6B | 478.0M | 1.3B | 1.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.4B | 1.6B | 479.0M | 1.3B | 1.3B |
| Per Share | |||||
| Basic EPS | $8.22 | $8.94 | $2.77 | $7.79 | $7.79 |
| Diluted EPS | $8.19 | $8.88 | $2.76 | $7.79 | $7.79 |
| Revenue Per Share | $47.90 | $47.82 | $47.66 | $47.46 | $47.14 |
| Shares | |||||
| Basic Shares Outstanding | 173.5M | 174.1M | 173.2M | 172.7M | 172.5M |
| Diluted Shares Outstanding | 174.4M | 175.3M | 173.7M | 172.7M | 172.5M |
| Profitability Metrics | |||||
| EBITDA | 2.6B | 2.5B | 1.5B | 2.2B | 2.3B |
| D&A | 636.0M | 489.0M | 555.0M | 561.0M | 578.0M |
| EBIT | 2.0B | 2.1B | 972.0M | 1.7B | 1.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026